Article: H.C. Wainwright Keeps a Buy Rating on Aravive (ARAV)

Article - Media

H.C. Wainwright Keeps a Buy Rating on Aravive (ARAV)

Austin Angelo

SmarterAnalyst, 30 April 2020

In a report released today, Joseph Pantginis from H.C. Wainwright maintained a Buy rating on Aravive (ARAV), with a price target of $15.00. The company’s shares closed last Thursday at $12.95.

According to TipRanks.com, Pantginis is a 5-star analyst with an average return of 14.5% and a 43.7% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Lineage Cell Therapeutics, and Iovance Biotherapeutics.

Read full article.

 

Comment: This company is at risk of collusion between a placement agent and naked short sellers.